WO2023026182 - SARS-COV-2 VACCINES
National phase entry is expected:
Publication Number
WO/2023/026182
Publication Date
02.03.2023
International Application No.
PCT/IB2022/057882
International Filing Date
23.08.2022
Title **
[English]
SARS-COV-2 VACCINES
[French]
VACCINS ANTI-SARS-COV-2
Applicants **
JANSSEN PHARMACEUTICALS, INC.
1125 Trenton-Harbourton Road
Titusville, New Jersey 08560, US
Inventors
SADOFF, Jerald C.
Washington, District of Columbia 20012, US
Priority Data
63/260,523
24.08.2021
US
21201187.8
06.10.2021
EP
63/262,365
11.10.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 3049 | |
| EPO | Filing, Examination | 32894 | |
| Japan | Filing | 587 | |
| South Korea | Filing | 639 | |
| USA | Filing, Examination | 13310 |
Total: 50479 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present invention relates to the use of an adenovirus comprising a nucleic acid encoding a coronavirus S protein comprising an amino acid sequence of SEQ ID NO: 1 for boosting the immune response against SARS CoV-2..[French]
La présente invention concerne l'utilisation d'un adénovirus comprenant un acide nucléique codant pour une protéine S de coronavirus comprenant une séquence d'acides aminés de SEQ ID NO : 1 pour renforcer la réponse immunitaire contre le SARS-CoV-2